Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s):  CPHRF

Healthcare
Cipher Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products either directly in Canada or indirectly through partners in Canada, the United States and South America. Its Dermatology products include Actikerall, Epuris, Ozanex and Vaniqa. Its Hospital Acute Care products include Aggrastat and Brinavess. Its Out-Licensed products include Absorica, ConZip and Lipofen. The Company is also focused on building a portfolio of prescription medicines that serve unmet medical needs. The Company's product pipeline development programs including MOB-015, DTR-001, and CF-101. The Company's subsidiaries include Cipher US Holdings Inc., Cipher US Holdco LLC, and Cipher Pharmaceuticals US LLC.


TSX:CPH - Post by User

Cipher Pharmaceuticals Inc > Rapid Growth of Isotrention Market in Q1/20
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(28)
•••
Comment by spike55on Aug 14, 2020 12:38pm
79 Views
Post# 31409168

RE:RE:RE:Rapid Growth of Isotrention Market in Q1/20

RE:RE:RE:Rapid Growth of Isotrention Market in Q1/20
pabaloo wrote: Exactly! The money will continue to roll in no hurry to do anything. 10 million a year for the foreseeable future. With Trulance and Trevyent possibly 15 million in royalties. Lots of possibilities and the downside is minimal. There is also almost 200 million in NOLS that can be used to offset tax gains. The future is bright no need to worry here just enjoy the ride.




Thats right in a low return world this stock will outperform.....I give it a 20X earnings (excluding Absorica)

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities